ETON PHARMACEUTIC WKN: A2N38G ISIN: US29772L1089 Forum: Aktien Thema: Hauptdiskussion

Bei dem Newsflow den es hier bald geben wird, sind 20 Dollar durchaus möglich, zumindest in der Spitze, zwischendurch wird es irgendwann eine KE geben, hoffen wir mal die kommt erst nach dem Pdufa Termin. Und natürlich auf gute News

Super Billi1 👍

H.C. Wainwright reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $21 to $23.

Die Spitze bei 7.90$ hätte ruhig bleiben können ;)

Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-and-xellia-pharmaceuticals-announce

Dabei muss man aber auch sagen opaleye Management ist in imprimis Investiert. Die besitzen 7mio shares von eton (*** Firma). Da kommen hoffentlich noch einige dazu wenn es zu den nächsten Zulassungen Anfang des Jahres geht.

2 institutionelle sind recht wenig, da ist noch Luft nach oben.

https://fintel.io/so/us/eton

Hoffentlich kommt die nächsten Monate noch ein bisschen volumen rein. Bei 11 Mio Aktien im Umlauf und soweit ich weiß keine institutionellen Anleger kann der Kurs ordentlich abgehen sobald etwas mehr Liquidität vorhanden ist.

https://seekingalpha.com/article/4313581-small-bet-on-eton-pharmaceuticals?utm_source=dashboard.stck.pro&utm_medium=referral

Nur alte Bekannte hier 🙋‍♂️

ANDA mit paragraph IV cerification für DS-300 wurde an die FDA übermittelt. Bausch health hat eine geänderte Fassung zu ihrem zurückgewiesen EM-100 Antrag an die FDA gesendet. https://ir.etonpharma.com/node/6766/html

Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-biorphenr

Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104 Business WireAugust 19, 2019, 1:00 PM GMT+2 DEER PARK, Ill.--(BUSINESS WIRE)-- ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019 https://finance.yahoo.com/news/eton-pharmaceuticals-announces-positive-results-110000902.html

ton Pharmaceuticals (ETON) Investor Presentation - Slideshow https://seekingalpha.com/article/4282869-eton-pharmaceuticals-eton-investor-presentation-slideshow?source=quotemedia_readmore

Second Quarter Financial Results Revenue: Eton reported no revenue in the second quarter of 2019 and no revenue for the same period in 2018. Research and Development (R&D) Expenses: R&D expenses were $1.4 million for the second quarter of 2019 versus $1.7 million for the same period in 2018. The decline was primarily driven by reduced product-specific development costs in the period, partially offset by increased costs associated with headcount and the operation of the company’s R&D laboratory facility that was set up in late 2018. General and Administrative (G&A) Expenses: G&A expenses were $1.9 million for the second quarter of 2019 versus $1.0 million for the same period in 2018. The increase was primarily driven by higher employee-related costs from increased headcount, public company expenses, and marketing expenses associated with product launch preparation activities. Excluding non-cash expenses, G&A expenses for the quarter were $1.5 million versus $0.6 million in the prior year period. Net Loss: Eton reported a net loss for the second quarter of 2019 of $3.2 million versus $3.1 million for the same period of 2018. Cash Position: As of June 30, Eton reported cash and cash equivalents of $14.9 million compared to $26.7 million as of December 31, 2018 and $19.6 million as of March 31, 2019. Subsequent to the quarter-end, in early July, Eton received a $1.3 million refund from the FDA for an NDA filing fee which had been paid in March 2019.